Tracy

[Tracy @tracyzhbme]

@biogerontology Looking forward to reading it! Impressive how Chinese hospitals are embracing AI, I wonder how much faster future clinical trials could be if AI agents could drive the process.

[Tracy @tracyzhbme]

Truly beautiful writing, better than the textbooks I have seen.

[Derya Unutmaz, MD @DeryaTR_]

I asked GPT-5.4 Pro to write a 10,000-word literary article on my beloved T cells, the army & defenders of our body. As I read through it, I am both mesmerized & deeply emotional; it's just so beautifully written! Here is a small snippet, & attached are the first few paragraphs.

"Somewhere in your lymph nodes, a naïve T cell is passing a dendritic cell and finding nothing of interest. Somewhere else, a memory T cell embedded in tissue waits like a banked ember. Somewhere, in a thymus grown quieter with time, fewer new cells are learning the ancient discipline of tolerance. Somewhere, in a tumor or an infected tissue, a T cell meets a peptide it was born to recognize. A synapse forms. Molecules gather. Thresholds are crossed. The future tilts.

This is how the body keeps its covenant with itself: not through certainty, but through innumerable acts of informed suspicion, disciplined response, and remembered encounter.

This is the work of T cells.

And it is marvelous."

[Tracy @tracyzhbme]

Looking forward to reading the thesis! Our industry has too many closed door discussions ;)

[Morgan Cheatham, MD @morgancheatham]

last week we hosted Breyer Capital's 4th Annual Healthcare and Life Sciences Summit in collaboration with The University of Texas in Austin.

it was a privilege to bring together the full breadth of healthcare and life sciences: from Centers for Medicare and Medicaid Services to Neuralink, from Google Research and Arc Institute to Lilly, from Abridge to UT MD Anderson.

[Tracy @tracyzhbme]

Seems like a data issue (apple health) and the health agents are just starting, as more people use it, it will improve much faster than a medical school student. Also, even in Boston, many people struggle to find a PCP and getting appointments within reasonable timeline.

[Eric Topol @EricTopol]

On the poor performance of ChatGPT Health in early assessment, by @geoffreyfowler
https://t.co/OXjlxrGnA3

[Tracy @tracyzhbme]

Congratulations! Good luck with Phase I! I can see the trial candidate profile is very carefully selected and it won't be a fast trial recruitment.

[David Sinclair @davidasinclair]

These trials will be a test of our Information Theory of Aging and the safety of our technology for the first time in humans
https://t.co/PupkSnDaEb

[Tracy @tracyzhbme]

wow, looking forward!

[Tracy @tracyzhbme]

Applaud them for trying to build tools for the world to advance science.

[a16z @a16z]

Priscilla Chan and Mark Zuckerberg on Curing All Disease

We sat down with Dr. Priscilla Chan and Mark Zuckerberg, co-founders of the Chan Zuckerberg Initiative, to discuss their ambitious plan to cure, prevent, and manage all disease by the end of the century.

CZI’s Biohub aims to generate vast biological datasets to train new frontier AI models to guide scientists in the lab, creating a feedback loop to accelerate the pace of basic science and take us towards a world without disease.

00:00 Introduction
03:42 Building tools to accelerate scientific discovery
07:03 Biohub = Frontier Biology + Frontier AI
13:32 "Most diseases should be thought of as rare diseases”
15:39 Inspiration: building a periodic table for biology
19:27 Why virtual cells?
21:17 The Biohub master plan
33:36 The importance of interface design in democratizing scientific discovery
35:34 How Biohub encourages cross-functional collaboration
40:38 Looking ahead: the broader impact of AI on biotech

@bhorowitz @vintweeta @eriktorenberg

[Tracy @tracyzhbme]

$245 a month is a big discount!

[STAT @statnews]

Novo Nordisk's Wegovy, Eli Lilly's Zepbound to be sold at discounted prices on TrumpRx, covered by Medicare. https://t.co/ZrnJ3ZlfXJ

[Tracy @tracyzhbme]

@morgancheatham But you do need your pager :D

[Tracy @tracyzhbme]

@statnews Agree. This is a much bigger setback for LNP delivered RNA therapeutics than people want to admit.

[Tracy @tracyzhbme]

The latest NEJM publication reports strong Phase 3 results in China for #Telitacicept, a first-in-class dual inhibitor of #BLyS and #APRIL, in systemic lupus erythematosus (#SLE).
📊 Trial Highlights
Primary Endpoint: 67.1% SRI-4 response at 52 weeks vs. 32.7% placebo (P<0.001).
Steroid-Sparing: 44.9% achieved ≤7.5 mg/day or ≥25% dose reduction.
Safety: Mostly mild-to-moderate AEs; manageable infection risk.
💡 This Is Big for @VorBio
Exclusive Rights: @VorBio now holds U.S. and ex-China global rights for #Telitacicept under a $125M deal with @RemeGen, with milestones >$4B and tiered royalties.
Market Opportunity: U.S. SLE prevalence ~200K patients; biologics adoption growing. Potential expansion into gMG and RA (approved in China) could unlock multi-billion-dollar revenue streams.
Strategic Fit: Vor Bio’s expertise in immune modulation and cell engineering positions it to accelerate development and maximize commercial success.
📖 Read the NEJM article: https://t.co/gwi1WEI5RQ
👉 Could Telitacicept redefine the standard of care for SLE and beyond?
#Autoimmune #SLE #Biologics #VorBio #Telitacicept #NEJM #ClinicalTrials #Innovation #Healthcare

[Tracy @tracyzhbme]

Making the test reliable and accessible will be key.

[Eric Topol @EricTopol]

Someday, especially in older adults, getting an immunome will be routine. Here's @Duncande's @techreview https://t.co/YDIwjKK58J

[Tracy @tracyzhbme]

Thank you! Was great event and looking forward to more opportunities for science and research in this community!

[DeSci Boston @DeSciBoston]

🌟Big thanks to everyone who joined us at MIT Media Lab — speakers, builders, sponsors and community alike. Let’s keep building and redefining what science can be.
#DeSci

@BioProtocol @Aura_Sci @hetu_protocol @ChainforGood @AntLab_rwa @quipnetwork @AllInXGlobal @blockchainwk

[Tracy @tracyzhbme]

30% overhead is still significant but much better than current academic institutes

[Bio Protocol @BioProtocol]

How Bio works in a nutshell 🧪

Send this to your normie friends.

[Tracy @tracyzhbme]

@BioProtocol 30% overhead is still significant, but I guess better than current academic institutes

[Tracy @tracyzhbme]

Dan and his family have done so much to push forward the field of research and clinical trials for FSHD. It is a huge loss to the community.

[Muscular Dystrophy Association @MDAorg]

We join our colleagues at the @FSHDSociety &amp; the neuromuscular community in mourning the loss of Daniel Perez, co-founder of the FSHD Society. His vision &amp; determination created a powerful movement that has driven research forward &amp; united countless families living with FSHD.

[Tracy @tracyzhbme]

@brian_armstrong @Google Things moving so fast

[CyberCat @CyberCatX]

🔥 $LMND 1年翻3倍，但长期投资的红利才刚刚开始，10倍是我的bear case：

很多人可能没有意识到 $LMND 只是一个成立了的10年的年轻公司。这些年私营公司从成立到IPO的平均年限是9-14年，与众多仍然躲在VC/PE襁褓中的公司不同，Lemonade在5岁时就上市，早早的进入了社会磨练，经历了周期的检验。

$LMND 在2020年上市，经历了Covid，经历了加息/流动性紧缺周期，经历了通胀高赔付。真金不怕火炼，无数的痛苦与磨练让lemonade已经脱胎换骨成为了一个独当一面的少年，有着与其年龄不符的成熟：数据模型和AI基建成熟，现金流转正，明年即将盈利，我们已经要到了收获的季节。我认为lemonade 一定是AI应用赛道首先跑出来的几家公司。

非投资建议，短期的走势没人能预测，但是我个人认为长期投资 $LMND 的投资回报/风险比例是相当诱人的。目前的lemonade 只有4B的估值，市场终将醒来，长期投资者将享受到早期投资AI公司的丰厚回报。

[宝玉 @dotey]

在昨天 GPT-5 Codex 发布之前，我是推荐 Claude Code 的，不过经过我一天测试下来，以及社区的积极反馈，我现在推荐 GPT-5 Codex 为主，Claude Code 为辅，或者可以取消订阅。

GPT-5 Codex 的用量还可以，使用你的 ChatGPT Plus 订阅就可以用蛮久，具体我不太清楚。如果不够用就要升级 ChatGPT Pro，但是要 $200/月，如果你经常写代码可以考虑。

我现在主要的 AI 订阅是：
ChatGPT Pro：$200
Claude Max x5: $100
Gemini Pro: $20
GitHub Copilot: $10

接下来会把 Claude 降级为 Claude Pro: $20 ，其余不变

[Tracy @tracyzhbme]

@dotey AI届太卷了！ 消费者很爽